Back to search
FDAFDA · Food and drugs·Recall number D-0202-2025

glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC: 60687-480-21, Unit Dose NDC: 60687-480-11

Published January 22, 2025 · Recall initiated: December 17, 2024

Summary

FDA records drug Class II recall D-0202-2025, published January 22, 2025 and initiated December 17, 2024. Recalling firm: Amerisource Health Services LLC; Status: Terminated; Reported quantity: 2,028 units (cartons of 30 individual unit doses); Lot: Lot # 1012910, Exp Date: 04/30/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications:

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerisource Health Services LLC
Distributor
Nationwide in the USA
Lot
Lot # 1012910, Exp Date: 04/30/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC: 60687-480-21, Unit Dose NDC: 60687-480-11 recalled?

Yes. FDA published recall D-0202-2025 on January 22, 2025. Reported hazard: Failed Dissolution Specifications:

What should I do if I have this product?

Voluntary: Firm initiated · Letter